Intercept Pharmaceuticals Stock Price. Everything You Need To Know About The Intercept Pharmaceuticals Stock!
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 341 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.
Intercept Pharmaceuticals Stock Price. Everything You Need To Know About The Intercept Pharmaceuticals Stock! performance
- Employees 341
- Company HQ Morristown
- Website https://www.interceptpharma.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
Looking to invest in Intercept Pharmaceuticals? You’ve come to the right place. As a leading investment platform, Zorion offers retail investors from Malaysia, Thailand, Indonesia, and Vietnam the opportunity to invest in real US stocks like Intercept Pharmaceuticals. With our investment insights and recommendations, you can make informed decisions about your investment. But it doesn’t stop there. We provide access to a wealth of resources and educational materials to help you further your investment knowledge. Whether you’re based in Malaysia, Thailand, Indonesia, or Vietnam, Zorion is here to support you on your investment journey. Invest in Intercept Pharmaceuticals today and seize the potential for growth and success.
